Valion Bio Inc (VBIO) - Total Liabilities
Based on the latest financial reports, Valion Bio Inc (VBIO) has total liabilities worth $14.81 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Valion Bio Inc (VBIO) cash flow conversion to assess how effectively this company generates cash.
Valion Bio Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Valion Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See what is Valion Bio Inc's book value for net asset value and shareholders' equity analysis.
Valion Bio Inc Competitors by Total Liabilities
The table below lists competitors of Valion Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
India | Rs228.60 Million |
|
Proteak Uno S.A.B. de C.V
MX:TEAKCPO
|
Mexico | MX$3.48 Billion |
|
Green Minerals AS
OL:GEM
|
Norway | Nkr477.00K |
|
Shyam Telecom Limited
NSE:SHYAMTEL
|
India | Rs457.22 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
India | Rs531.88 Million |
|
City Of London Investment Group
LSE:CLIG
|
UK | GBX23.42 Million |
|
Pacific Resources Limited
AU:PXR
|
Australia | AU$1.60 Million |
|
Bathurst Metals Corp
V:BMV
|
Canada | CA$187.04K |
Liability Composition Analysis (2017–2025)
This chart breaks down Valion Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Valion Bio Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valion Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valion Bio Inc (2017–2025)
The table below shows the annual total liabilities of Valion Bio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.81 Million | +5344.85% |
| 2024-12-31 | $272.00K | -82.75% |
| 2023-12-31 | $1.58 Million | -29.76% |
| 2022-12-31 | $2.25 Million | +6613.52% |
| 2020-12-31 | $33.44K | -97.40% |
| 2019-12-31 | $1.28 Million | +263.45% |
| 2017-12-31 | $353.52K | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more